Jason T. Rich, MD - Otolaryngology–Head ...

Dr. Jason Rich, M.D.

Claim this profile

Washington University School of Medicine

Studies Squamous Cell Carcinoma
Studies Head and Neck Cancers
6 reported clinical trials
11 drugs studied

Area of expertise

1

Squamous Cell Carcinoma

Jason Rich, M.D. has run 3 trials for Squamous Cell Carcinoma. Some of their research focus areas include:

Stage III
p16 positive
p16 negative
2

Head And Neck Cancers

Jason Rich, M.D. has run 2 trials for Head and Neck Cancers. Some of their research focus areas include:

Stage III
HPV negative
Stage IV

Affiliated Hospitals

Image of trial facility.

Washington University School Of Medicine

Clinical Trials Jason Rich, M.D. is currently running

Image of trial facility.

Radiation, Cisplatin, and Surgery

for Throat Cancer

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA. Most cases of OPSCC (\>90%) are caused by the human papillomavirus (HPV) and are often cured with current therapy. However, patients treated with surgery followed by postoperative adjuvant chemotherapy and radiation therapy (POA(C)RT) still experience substantial morbidity. In this highly curable disease, current clinical research interest is focused on investigation of de-escalated therapy, with the goal to reduce treatment-related adverse events (AEs) while maintaining a low recurrence rate. In this study, patients with HPV-related OPSCC will undergo resection of the primary tumor site and involved/at-risk regional neck nodes. Based on the pathology report, patients will be assigned to: * Arm 1 (de-POACRT-42 Gy) * Arm 2A (de-POART-42 Gy) * Arm 2B (de-POART-37.8 Gy) * Arm 2C (de-POACRT-30 Gy). All patients with high-risk pathology will be assigned to Arm 1 whereas patients with intermediate-risk pathology will be randomized (1:1:1) to Arm 2A, Arm 2B, or Arm 2C. Patients with highest-risk pathology and low-risk pathology will be removed from the trial after surgery and will be advised to pursue standard of care options.

Recruiting

1 award

Phase 2

6 criteria

Image of trial facility.

CUE-101

for Throat Cancer

This trial tests a new treatment called CUE-101 to see if it is safe and effective for patients with a specific type of throat cancer. The treatment aims to boost the immune system before standard cancer therapy. Patients are newly diagnosed and have not yet received any other treatments.

Recruiting

1 award

Phase 2

More about Jason Rich, M.D.

Clinical Trial Related

7 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Jason Rich, M.D. has experience with

  • Cisplatin
  • Radiation Therapy
  • CareOrbit
  • Cetuximab
  • Intensity-Modulated Radiation Therapy
  • Palbociclib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Jason Rich, M.D. specialize in?

Is Jason Rich, M.D. currently recruiting for clinical trials?

Are there any treatments that Jason Rich, M.D. has studied deeply?

What is the best way to schedule an appointment with Jason Rich, M.D.?

What is the office address of Jason Rich, M.D.?

Is there any support for travel costs?